The Opioid Overdose Epidemic in the United States

NCIPC/CDC Research Priorities

Tamara Haegerich, PhD
Associate Director for Science
Division of Unintentional Injury Prevention

NCIPC Board of Scientific Counselors Meeting
June, 2018
Outline of the Presentation

• Review CDC’s opioid strategy
• Present NCIPC opioid research priorities
• Review activities and summary of progress
• Describe how the epidemic has evolved since priorities were established
• Describe need to integrate opioid priorities with Center and Agency priorities

• NIH presentation of priorities
• BSC discussion of federal priorities and research gaps

• Request BSC input
Overview of CDC Opioid Strategy
Pillars of CDC Activity

- Conduct surveillance and research
- Empower consumers to make safe choices
- Build state, local, and tribal capacity
- Support providers, health systems, and payers
- Partner with public safety
Conduct surveillance and research

In the area of surveillance and research, CDC conducts analyses to:

- estimate the burden of opioid-related morbidity and mortality,
- track trends and the populations at greatest risk,
- identify modifiable risk and protective factors,
- evaluate the effectiveness of preventive interventions, and
- target the best ways to disseminate and implement promising strategies.

For example, as shown here, in March we released a Vital Signs in the MMWR on Opioid Overdoses Treated in Emergency... for opioid overdoses overall across the US within one year’s time, leveraging syndromic surveillance and medical claims data, illustrating how fast moving this epidemic is.

Opioid overdoses continued to increase in cities and towns of all types.*

Detecting recent trends in opioid overdose ED visits provides opportunities for action in this fast-moving epidemic.

**PERCENT CHANGE**
- Decrease
- Increase 1 to 24%
- Increase 25 to 49%
- Increase 50% or more
- Data unavailable

SOURCE: CDC’s Enhanced State Opioid Overdose Surveillance (ESOOS) Program, 16 states reporting percent changes from July 2016 through September 2017.
Build state, local, and tribal capacity

Overdose Prevention in States Initiative

Through our Overdose Prevention in States Initiative funded through three state funding opportunity announcements, CDC is currently supporting 45 states and Washington DC with funding and expertise to conduct activities such as:

- Reporting on nonfatal and fatal overdose
- Increasing comprehensive toxicology testing and supporting medical examiners and coroners
- Enhancing prescription drug monitoring programs
- Implementing and evaluating strategies to improve safe opioid prescribing,
- Implementing CDC's Rx Awareness communication campaign

We are currently working to further scale up these activities across the nation with our funding increase.

PDMPs
System-Level
Evaluate Policy
Surveillance
Rapid Response

Prevention for States (PFS)
Data-Driven Prevention Initiative (DDPI)
Enhanced Morbidity-Mortality Surveillance (ESOOS)
Unfunded State
Support providers, health systems, and payers

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

Checklist for prescribing opioids for chronic pain

For primary care providers treating adults (18+) with chronic pain ≥3 months, excluding cancer, palliative, and end-of-life care

**Checklist**

**When CONSIDERING long-term opioid therapy**
- Set realistic goals for pain and function based on diagnosis (e.g., walk around the block).
- Check that non-opioid therapies tried and optimized.
- Discuss benefits and risks (e.g., addiction, overdose) with patient.
- Evaluate risk of harm or misuse.
  - Discuss risk factors with patient.
  - Check prescription drug monitoring program (PDMP) data.
  - Check urine drug screens.
- Set criteria for stopping or continuing opioids.
- Assess baseline pain and function (e.g., PEG scale).
- Schedule initial reassessment within 1–4 weeks.
- Prescribe short-acting opioids using lowest dosage on product labeling; match duration to scheduled reassessment.

**If RENEWING without patient visit**
- Check that return visit is scheduled ≤3 months from last visit.

-provider & patient materials developed-

**Evidence About Opioid Therapy**
- Benefits of long-term opioid therapy for chronic pain not well supported by evidence.
- Short-term benefits equal to moderate for pain, function.
- Insufficient evidence for long-term benefits in non-treatment settings.

**Non-Opioid Therapies**
Use alone or combined with opioids as indicated:
- Non-opioid medications (e.g., NSAIDs, TCAs, SNRIs, and add-on medications).
- Physical treatments (e.g., exercise therapy, weight loss).
- Additional treatment (e.g., CBT).
- Procedures (e.g., intra-articular corticosteroids).

**Evaluating Risk of Harm or Misuse**
Kanaw risk factors include:
- Illegal drug use, prescription drug abuse in the past 3 months.
- History of substance use disorder or overdose.
- Mental health conditions (e.g., depression, anxiety).

Continuing Education Examination available at http://www.cdc.gov/mmwr/vol65/rr1.htm

- U.S. Department of Health and Human Services
  Centers for Disease Control and Prevention
Support providers, health systems, and payers

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

Checklist for prescribing opioids for chronic pain

For primary care providers treating adults (18+) with chronic pain ≥3 months, excluding cancer, palliative, and end-of-life care

**CHECKLIST**

**When CONSIDERING long-term opioid therapy**
- Check that non-opioid therapies were tried and optimized.
- Discuss benefits and risks (eg, addiction, overdose) with patient.
- Evaluate risk of harm or misuse.
  - Discuss risk factors with patient.
  - Check prescription drug monitoring program (PDMP) data.
  - Check urine drug screens.
- Set criteria for stopping or continuing opioids.
- Assess baseline pain and function (eg, PEG scale).
- Schedule initial reassessment within 1–4 weeks.
- Prescribe short-acting opioids using lowest dosage on product labeling; match duration to scheduled reassessment.

**If RENEWING without patient visit**
- Check that return visit is scheduled ≤3 months from last visit.

**EVIDENCE ABOUT OPIOID THERAPY**
- Amounts of long-term opioid therapy for chronic pain are not well supported by evidence.
- Short-term benefits are modest for pain, function, and health-related quality of life.
- Long-term evidence for long-term benefits in low back pain, headache, and fibromyalgia.

**NON-OPIOID THERAPIES**
- Use alone or combined with opioids, as indicated:
  - Non-opioid medications (eg, NSAIDs, TCAs, SNRIs, anti-convulsants).
  - Physical treatments (eg, exercise therapy, weight loss).
  - Behavioral treatment (eg, CBT).
  - Procedures (eg, intra-articular corticosteroids).

**EVALUATING RISK OF HARM OR MISUSE**
- Known risk factors include:
  - Illegal drug use or prescription drug abuse for non-medical reasons.
  - History of substance use disorder or overdose.
  - Mental health conditions (eg, depression, anxiety).

Provider & Patient Materials Developed
Partner with public safety

- Heroin Response Strategy within High Intensity Drug Trafficking Areas (HIDTAs)
- Public health-public safety connections
- Community projects to evaluate innovative local responses to overdose spikes
Empower consumers to make safe choices

Prescription opioids can be **addictive and dangerous.**

It only takes a little to lose a lot.

cdc.gov/RxAwareness
NCIPC Opioid Research Priorities
NCIPC Research Priorities

Four priority areas to identify factors that increase risk for opioid mortality, generate prevention strategies that work, and inform ways to enhance implementation.

1. Evaluate Insurance Mechanisms (FORMULARY MANAGEMENT)
   Evaluate the impact of insurer mechanisms and pharmacy benefit manager strategies to change prescribing behavior, inappropriate use of controlled substances, and patient outcomes.

2. Evaluate State Policies and Strategies (PDMP/POLICY)
   Evaluate the impact of state policies and strategies that facilitate PDMP use, improve prescribing practices, educate patients, and encourage treatment overdose and response.

3. Identify Risk and Protective Factors (RX TO ILLICIT)
   Identify factors that increase risk for prescription drug-related mortality, and identify risk and protective factors related to the co-use of prescription opioid pain relievers and heroin.

4. Identify Dissemination and Implementation Methods (CLINICAL CARE)
   Evaluate the adoption, implementation, and impact of clinical practice guidelines, clinical decision supports, and coordinated care plans within primary care practices in health systems.

Evaluate insurance mechanisms (FORMULARY MANAGEMENT)

• Which insurance and pharmacy benefit manager interventions change prescribing behaviors most effectively (e.g., drug utilization review, patient review and restriction, prior authorization)?

• Which of these interventions are most cost-effective?

• What are the effective ways that state public health departments can engage insurers and pharmacy benefit managers to foster adoption of these interventions?
Evaluate state polices and strategies (PDMP/POLICY)

- What are the impacts of innovative, untested policies and strategies at the state level on prescribing rates and prescription or illicit drug misuse, abuse, and overdose?

- What are the potential unintended consequences (e.g., encouraging transition from prescription opioid misuse to illicit drug misuse)?

- What are the impacts of harm-reduction strategies on drug overdose?

- Which PDMP strategies (e.g., mandatory registration) enhance use and produce the greatest impacts on prescribing and health outcomes?

- What are the cost implications and cost savings of identified policy changes?

- How can communication campaigns influence physician opioid prescribing and patient opioid use?
Identify risk and protective factors (RX TO ILLICIT)

• How can PDMP, coroner, medical examiner, and law enforcement data be used to identify risk and protective factors for drug overdose?

• What are the patterns of co-use of prescription opioids and heroin, injection of opioids, and overdose?

• Does controlled substance prescribing, including opioid pain reliever prescribing, increase risk for heroin overdose?
Identify dissemination and implementation methods (CLINICAL CARE)

• What are the clinical decision support needs, barriers, and effective approaches to promoting guideline adherence in primary care?

• What factors facilitate adoption of coordinated care plans in health systems?

• What are the patient and health system impacts of guideline, clinical decision support, and coordinated care plan implementation?
Review of Activities and Summary of Progress
## Extramural Funding Opportunities 2012-2019

<table>
<thead>
<tr>
<th>Research Area</th>
<th>Year(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research to Prevent Prescription Drug Overdoses</td>
<td>2012, 2014</td>
</tr>
<tr>
<td>Research on Integration of Injury Prevention in Health Systems</td>
<td>2014</td>
</tr>
<tr>
<td>Research on Rx Opioid Use, Rx Prescribing, and Heroin Risk</td>
<td>2016</td>
</tr>
<tr>
<td>Research to Evaluate Medication Management to Reduce Falls</td>
<td>2018</td>
</tr>
<tr>
<td>Research for the Primary/Secondary Prevention of Opioid Overdose</td>
<td>2018</td>
</tr>
<tr>
<td>Injury Control Research Centers</td>
<td>2014, 2019</td>
</tr>
</tbody>
</table>
Funded extramural opioid research: Distribution of ICRC and cooperative agreement activities across states, 2012-2018 (N-23)

Here is a data visualization of our funded extramural research projects from 2012 to 2018 using our newly developing Research Priorities Database. This database is being developed to help NCIPC track investments in research across all of our topic areas. For this report, we have pulled a few data visualizations to show you its potential. Here you can see the distribution of extramural opioid research. In particular, ICRC and cooperative agreement activities across states, with the total funding amount to support these projects during this time period. These are the projects currently in progress that are associated with the funding announcements presented in the previous slide. Note that the number of projects may appear low, as there are several funding announcements for FY18 and FY19 that do not yet have projects funded since review processes are still in progress.

Opioid Overdose: Distribution of Research Activities across ICRC's and Research Cooperative Agreements by Location FY12-Present. Total Opioid Overdose Research Activities (N=23).

© OpenStreetMap contributors
Funded extramural opioid research: Distribution of ICRC and cooperative agreement activities across priorities, 2012-2018 (N=23)

<table>
<thead>
<tr>
<th>Research Priority</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluate the adoption, implementation, and impact of clinical practice guidelines</td>
<td>11</td>
</tr>
<tr>
<td>Evaluate the impact of insurer mechanisms and pharmacy benefit manager strategies</td>
<td>6</td>
</tr>
<tr>
<td>Evaluate the impact of state policies and strategies that facilitate Prescription</td>
<td>4</td>
</tr>
<tr>
<td>Drug Monitoring Program use, improve prescribing practices, educate patients, and</td>
<td></td>
</tr>
<tr>
<td>encourage treatment and overdose response</td>
<td></td>
</tr>
<tr>
<td>Identify factors that increase risk for prescription drug-related mortality and</td>
<td>7</td>
</tr>
<tr>
<td>identify risk and protective factors related to the co-use of prescription opioid</td>
<td></td>
</tr>
<tr>
<td>pain relievers and heroin</td>
<td></td>
</tr>
</tbody>
</table>

*Each research activity may address multiple research priorities

Data last updated 6/6/2018 9:52:17 AM
Funded Projects: Evaluate insurance mechanisms (FORMULARY MANAGEMENT)

- 3 NOFOs, 4 projects funded
  - Medicaid lock-in, North Carolina (PI: Skinner)
  - Worker’s compensation/SSDI-eligible disabled Medicare cost sharing and closed formulary, Texas and California (PI: Mulcahy)
  - Medicaid prior authorization programs in 3 states (PI: Hartung)
  - Medicaid prior authorization, Pennsylvania (PI: Cochran)
Funded Projects: Evaluate state policies and strategies (PDMP/POLICY)

- 3 NOFOs, 3 projects funded
  - PDMP use in 7 states, impact on prescribing and health outcomes (PI: Green)
  - PDMP implementation within multi-component community strategy (Project Lazarus), impact on fatal and nonfatal overdose (PI: Ringwalt)
  - PDMP and pain clinic legislation, impact on prescribing behavior and use in 2 states (PI: Alexander)
Funded Projects: Identify risk and protective factors (RX TO ILLICIT)

• 2 NOFOs, 5 projects funded
  – Qualitative investigation of transitions from rx opioids to heroin (PI: Davidson)
  – Evaluation of changes in prescribing in safety net clinics and association with heroin initiation and overdose (PI: Coffin)
  – Evaluation of performance improvement in coordinated care organizations and impact on prescribing, opioid use, and Rx/illicit overdose (PI: Hartung)
  – Evaluation of associations between dose reduction/discontinuation, heroin use, and overdose (PI: Bohnert)
  – Evaluation of opioid reduction policies (e.g., quantity limits, MME) association with heroin use and overdose (PI: Binswanger)
Funded Projects: Identify dissemination/implementation methods (CLINICAL CARE)

• 5 NOFOs, 6 projects funded
  – Evaluation of clinical guidelines within Project Lazarus, examining impact on fatal and nonfatal overdose (PI: Ringwalt)
  – Evaluation of electronic health record alerts with feedback to providers on prescribing behaviors (PI: Seymour)
  – Evaluation of a safe opioid prescribing protocol in a trauma center on prescribing behavior and naloxone use (PI: Baird)
  – Evaluation of performance improvement efforts in coordinated care organizations on prescribing and initiation of heroin use (PI: Hartung)
  – Evaluation of implementation of dose reduction/discontinuation recommendations and associations with heroin use and overdose (PI: Bohnert)
In an evaluation of **Oregon Medicaid's prior authorization policy** for high dose opioids, the probability of an opioid fill over 120 MME declined, fills of non-opioid medications to treat neuropathic pain increased, and the probability of multiple pharmacy used declined significantly.¹

In an evaluation of **Florida's prescription monitoring program and pill mill law**, high risk patients experienced relative reductions in MME, total opioid volume, and number of dispensed opioid prescriptions, while low-risk patients generally did not experience significant relative reductions.²

In an evaluation of **Project Lazarus**, a state-wide initiative to prevent opioid overdose, provider education and policies to limit emergency department opioid dispensing were associated with lower overdose mortality.³

---

Injury Control Research Centers

• 6 ICRCs, 9 projects, Opioid Thematic Network
  – Evaluate mobile tools to educate ED patients about opioids
  – Evaluate state medical board policy to identify excessive prescribing using PDMP
  – Analyze poison control data to assess overdose among adolescents
  – Examine diagnoses and prescribing associated with OUD and overdose
  – Assess availability of county and regional interventions to address misuse
  – Translate opioid overdose prevention strategies
  – Evaluate prescription drug coverage policy on falls and overdose in older adults
  – Evaluate a brief intervention in EDs for at-risk individuals
  – Evaluate a home visitation program after overdose
  – Expand mindfulness-based relapse prevention in an outpatient setting for OUD
Sample of Intramural Research

Formulary Management
- Declines in opioid prescribing policy change in Massachusetts
- Associations among Medicaid preferred drug lists, methadone prescribing, and overdose
- Impact of prior authorization policies on opioid prescribing

PDMP/Policy
- Impact of mandatory PDMP and pill mill legislation on prescribing and overdose
- Systematic review of the impact of state policy and systems-level strategies on opioid overdose
- Impact of proactive reporting on prescriber behavior

Prescription to Illicit
- Increase in and characteristics of drug overdose deaths involving fentanyl*
- Demographic and substance use trends among heroin users*
- Trends in deaths involving heroin and synthetic opioids and law enforcement drug product reports*

Clinical Care
- Changes in opioid prescribing in the US, before and after CDC prescribing Guideline
- Advancing safer and more appropriate prescribing in Kaiser Permanente
- Evaluation of quality improvement and coordinated care plans on opioid prescribing and patient outcomes

Intramural research includes:
- Intramural secondary data analysis
- Contract data collection
- Partnership efforts

* Surveillance activities supporting research
An Evolving Epidemic
RISE IN OPIOID DEATHS | An Evolving Epidemic
Overdose deaths involving opioids by type of opioid, United States, 1999-2016

3 Waves
More than 350,000 people have died from an opioid overdose since 1999

Natural and semi-synthetic opioids
like oxycodone or hydrocodone

Synthetic opioids
like fentanyl

Heroin

Methadone

Rise in Prescription Opioid Deaths

1st Wave

Over 200,000 people have died from prescription opioids since 1999

Natural and semi-synthetic opioid death rate increased 4-fold from 1999 to 2011

Methadone death rate increased 6-fold from 1999 to 2007

Rise in Heroin Deaths

2\textsuperscript{nd} Wave

Over 60,000 people have died from heroin since 2010

Heroin death rate has increased over 5-fold since 2010

Rise in Synthetic Opioid Deaths – Likely Illicit Fentanyl

3rd Wave
Deaths from synthetic opioids (excluding methadone) doubled from 2015 to 2016

Synthetic opioid death rate (excluding methadone) increased more than 6-fold from 2013 to 2016

Rise in Synthetic Opioid Deaths – Likely Illicit Fentanyl

3rd Wave

Deaths from synthetic opioids (excluding methadone) doubled from 2015 to 2016.

Synthetic opioid death rate (excluding methadone) increased more than 6-fold from 2013 to 2016.

Rates of Rx opioid sales, deaths, and substance abuse treatment admissions, 1999-2010


November 2011
Today’s Heroin Epidemic
### Heroin Use Has INCREASED Among Most Demographic Groups

<table>
<thead>
<tr>
<th>Category</th>
<th>2002-2004*</th>
<th>2011-2013*</th>
<th>% CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SEX</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2.4</td>
<td>3.6</td>
<td>50%</td>
</tr>
<tr>
<td>Female</td>
<td>0.8</td>
<td>1.6</td>
<td>100%</td>
</tr>
<tr>
<td><strong>AGE, YEARS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-17</td>
<td>1.8</td>
<td>1.6</td>
<td>--</td>
</tr>
<tr>
<td>18-25</td>
<td>3.5</td>
<td>7.3</td>
<td>109%</td>
</tr>
<tr>
<td>26 or older</td>
<td>1.2</td>
<td>1.9</td>
<td>58%</td>
</tr>
<tr>
<td><strong>RACE/ETHNICITY</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic white</td>
<td>1.4</td>
<td>3</td>
<td>114%</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>1.7</td>
<td>--</td>
</tr>
<tr>
<td><strong>ANNUAL HOUSEHOLD INCOME</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than $20,000</td>
<td>3.4</td>
<td>5.5</td>
<td>62%</td>
</tr>
<tr>
<td>$20,000–$49,999</td>
<td>1.3</td>
<td>2.3</td>
<td>77%</td>
</tr>
<tr>
<td>$50,000 or more</td>
<td>1</td>
<td>1.6</td>
<td>60%</td>
</tr>
<tr>
<td><strong>HEALTH INSURANCE COVERAGE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>4.2</td>
<td>6.7</td>
<td>60%</td>
</tr>
<tr>
<td>Medicaid</td>
<td>4.3</td>
<td>4.7</td>
<td>--</td>
</tr>
<tr>
<td>Private or other</td>
<td>0.8</td>
<td>1.3</td>
<td>63%</td>
</tr>
</tbody>
</table>
Heroin use is part of a larger substance abuse problem.

Nearly all people who used heroin also used at least 1 other drug.

Most used at least 3 other drugs.

Heroin is a highly addictive opioid drug with a high risk of overdose and death for users.

People who are addicted to...

- Alcohol: 2x more likely to be addicted to heroin.
- Marijuana: 3x more likely to be addicted to heroin.
- Cocaine: 15x more likely to be addicted to heroin.
- Rx Opioid Painkillers: 40x more likely to be addicted to heroin.


https://www.cdc.gov/vitalsigns/heroin/index.html
Number of law enforcement encounters testing positive for fentanyl is rising dramatically. During the same time period, fentanyl prescriptions are relatively stable.
Opioid overdoses treated in emergency departments

Coordinated, informed efforts can better prevent opioid overdoses and deaths

- Offer naloxone and training to patient’s family and friends, in case the patient has another overdose.
- Connect patients with hospital case managers or peer navigators to link them to follow-up treatment and services.
- Plan for the increasing number of patients with opioid-related conditions, including overdose, injection-related concerns, and withdrawal.

Mental Health and Substance Abuse Treatment Providers
- Increase treatment services, including MAT for OUD.
- Increase and coordinate mental health services for conditions that often occur with OUD.

Local Emergency Department
- Get adequate supply and training for naloxone administration.
- Identify changes in illicit drug supply and work with state and local health departments to respond effectively.
- Collaborate with public health departments and health systems to enhance linkage to treatment and services.

First Responders | Public Safety | Law Enforcement Officers
- Connect with organizations in the community that provide public health services, treatment, counseling, and naloxone distribution.

Community Members

Community-Based Organizations
- Assist in mobilizing a community response to those most at risk.
- Provide resources to reduce harms that can occur when injecting drugs, including ones that offer screening for HIV and hepatitis B and C, in combination with referral to treatment and naloxone provision.

Local Health Departments
- Alert the community to the rapid increase in opioid overdoses seen in emergency departments and inform strategic plans and timely responses.
- Ensure an adequate naloxone supply.
- Increase availability and access to necessary services.
- Coordinate with key community groups to detect and respond to any changes in illicit drug use.
Integration with Other NCIPC Priorities
Integration with Other Injury Center Priorities
Adverse Childhood Experiences

**ACES can have lasting effects on...**

- **Health** (obesity, diabetes, depression, suicide attempts, STDs, heart disease, cancer, stroke, COPD, broken bones)
- **Behaviors** (smoking, alcoholism, drug use)
- **Life Potential** (graduation rates, academic achievement, lost time from work)

ACEs have been found to have a graded dose-response relationship with 40+ outcomes to date.

*This pattern holds for the 40+ outcomes, but the exact risk values vary depending on the outcome.*
Integration with Other Injury Center Priorities
Suicide Prevention

Preventing Suicide: A Technical Package of Policy, Programs, and Practices
Integration with Agency Priorities: Opioid Research Coordinating Unit
## Opioid Research Coordinating Unit

**Opioid Overdoses and Other Opioid-Related Harms: A CDC Roadmap for Prevention**

<table>
<thead>
<tr>
<th>FOCUS AREAS</th>
<th>OUTCOMES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FOCUS AREAS</strong></td>
<td><strong>MEDIUM-TERM</strong></td>
</tr>
<tr>
<td>1. Conduct Surveillance and Research</td>
<td>• Decrease unsafe prescribing</td>
</tr>
<tr>
<td></td>
<td>• Increase use of non-opioid therapies for pain</td>
</tr>
<tr>
<td></td>
<td>• Decrease non-medical use of prescription opioids, use of illicit opioids, and use of illicitly-manufactured fentanyl</td>
</tr>
<tr>
<td>2. Build State, Local, and Tribal Capacity</td>
<td>• Decrease opioid injection and unsafe injection practices</td>
</tr>
<tr>
<td></td>
<td>• Increase use of effective opioid use disorder treatment including medication-assisted therapy</td>
</tr>
<tr>
<td>3. Support Providers, Health Systems, and Payers</td>
<td>• Increase use of comprehensive prevention services by populations at risk, including testing and treatment of infections related to opioid use and effective treatment for pregnant and postpartum women using opioids</td>
</tr>
<tr>
<td>4. Partner with Public Safety</td>
<td>• Increase use of opioid reversing drugs</td>
</tr>
</tbody>
</table>
ORCU Research Gap Analysis - Overdose

• Conduct demonstration projects to identify cost-effective methods to reach people using opioids non-medically in hidden populations and engage them in medication-assisted treatment, provision of naloxone and overdose prevention training, prevention, testing, and treatment for infectious and noninfectious sequelae of opioid use.
ORCU Survey of Other CDC Center Research Priorities

Birth Defects and Developmental Disabilities

• Understand the prevalence of and reasons for opioid use during pregnancy, including the specific opioids and medication combinations used
• Evaluate the link between prenatal opioid exposure and structural birth defects, including the potential role of co-factors such as infections or other medications
• Investigate the safety and risk for medications used to treat opioid use disorder for pregnant women and their infants to inform guidelines for treatment

Reproductive Health

• Identify the barriers for Ob-Gyns and Pediatricians to implementing maternal screening for opioid use
• Identify the factors that influence post-partum relapse for women who enter opioid use disorder treatment during pregnancy
• Evaluate models of care to improve post-partum counseling and supports for women with a history of opioid use disorder
Other CDC Center Research Priorities Cont... 

**HIV/HBV/HCV/STD**

- Develop comprehensive community-based approaches to prevent and treat consequences of opioid injection, including substance use disorder, overdose, HIV, hepatitis B and C, and sexually transmitted diseases among key populations including people who inject opioids and other drugs, and young people.
- Identify best strategies and develop models for implementing comprehensive community-based programs to prevent injection-related harms including blood-borne pathogens in non-urban settings.
- Identify cost-effective methods to reach people using opioids non-medically in hidden populations and engage them in prevention, testing, treatment for the infectious and noninfectious sequelae of opioid use, including early identification of youth at risk for opioid use and ensuring continuity of care and treatment for people after release from the criminal justice system.
Other CDC Center Research Priorities Cont. . .

Occupational Safety and Health

• Identify antecedents to opioid use. For example, how do work and work-related injuries relate to the use of opioids? What kind of prescribing guidelines (e.g., worker’s compensation prescribing guidelines) can provide a path to improved health outcomes?

• Understand opioid use at work. For example, how does the use of opioids at work impact worker safety and health? Is employer drug testing an effective strategy for reducing opioid-related work injuries? Do supportive workplace programs improve likelihood of recovery from an opioid drug dependence?

• Address the impacts of misuse and overdose in the workplace. For example, how does opioid misuse and overdose impact first responders? What is the effectiveness of personal protective equipment in protecting first responders? How effective are portable detection devices used by law enforcement to field-test for illicit opioids? What are the psychosocial and mental health impacts of potential exposure to opioids on emergency responders?
Presentation of NIH Priorities and BSC Discussion of Research Gaps
Request for BSC Recommendations
Key Questions for the BSC

• To what degree have the Center’s intramural and extramural research projects addressed the established opioid research priorities?
• Are the research priorities currently comprehensive enough to address the ongoing and changing epidemic?
• Is there a need to update the priorities due to the changing epidemic and need for Center and Agency coordination?
  ✓ What research gaps need to be addressed?
  ✓ What is the correct balance of maintaining “old” priorities and establishing “new” priorities?
Food for thought – Initial brainstorming

• **Basic epidemiology and etiologic research**
  – Identify ways to improve death investigations and reporting (e.g., protocols, tox testing, intent, circumstances)
  – Identify how risk and protective factors may differ for Rx and illicit opioids
  – Identify populations most at risk and how strategies may need to be tailored (e.g., unemployed, adults with suicidal ideation or history of adverse childhood experiences)

• **Effectiveness research**
  – Evaluate strategies that support public health/public safety partnerships, implement harm reduction approaches, and enhance linkage to treatment for OUD
  – Evaluate unintended consequences of strategies (e.g., clinical policies, public safety), such as transition to illicit use, suicidal behavior, and child protection removal as a result of parent help-seeking
Food for thought – Initial brainstorming (2)

- Dissemination and implementation research
  - Evaluate models of provider training and education
  - Identify approaches used internationally and adapt for the US context

- Communications research
  - Identify the most effective messages, messengers, tools, and delivery models for preventing Rx and illicit opioid misuse
  - Identify methods for addressing stigma surrounding OUD, overdose, disclosure, help-seeking, and naloxone among the public, healthcare providers, public safety professionals, and EMS providers
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

For more information please contact Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30333
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348
E-mail: cdcinfo@cdc.gov  Web: www.cdc.gov